Data Presented Today at the American Stroke Association's International Stroke Conference
Nashville, TN – February 11, 2015 – iRhythm Technologies, Inc. , a leading digital health care solutions company focusing on the advancement of cardiac care, presented study results that demonstrate high compliance among patients using long term electrocardiogram (ECG) patch monitors to detect atrial fibrillation (AFib). The data was presented today at the American Stroke Association's International Stroke Conference, which is taking place in Nashville, TN.
iRhythm performed a retrospective analysis and found patients wearing the company's ZIO® XT Patch, had a high median percentage of leads on and percent of analyzable time, at 100% and 98%, respectively. The primary endpoint of leads on is the percentage of time the device is on the patient during the prescribed wear time and the analyzable time is the percentage of ECG record that was available for detection. The high patient compliance and large volume of quality ECG data obtained resulted in a timely and definitive diagnosis of AFib, which is often difficult to detect.
"This is important to monitor stroke patients for AFib as early detection and treatment can prevent a secondary stroke from occurring," said Judy Lenane, RN, MHA, executive vice president and chief clinical officer of iRhythm Technologies, Inc. "High patient compliance enables providers to obtain higher quality of data and provide a more definitive diagnosis."
iRhythm's ZIO® Service, which includes the ZIO XT Patch, proprietary algorithms and the ZIO Report, is revolutionizing how cardiac arrhythmias, including atrial fibrillation, are diagnosed. The ZIO Service provides the only long-term continuous monitoring approach that is proven to help clinicians rule in and rule out arrhythmias earlier in the diagnostic pathway and to change patient management. Clearance for the ZIO was granted by the U.S. Food and Drug Administration (FDA) in 2009 and became commercially available in 2011. Since then, the ZIO Service has been used with nearly 300,000 patients at nearly 1,000 institutions across the U.S. The ZIO Service also received CE Mark in late 2014 and is available in the United Kingdom.
About iRhythm Technologies, Inc. iRhythm is a privately held digital health company that is working to be the world leader in cardiac arrhythmia information. iRhythm develops and commercializes FDA-cleared solutions that integrate consumer-friendly biosensor technology, vast patient data, powerful analytics and medical expertise. Its flagship solution, the ZIO Service, offers a proven approach to long-term continuous monitoring that enables diagnosis earlier in the clinical pathway to improve patient outcomes and reduce healthcare costs. For more information, please visit www.irhythmtech.com.
Media Contact
Amanda Breeding
415-229-7649